Table 1.
S. No | Desired characteristics |
---|---|
1. | Safe to be administered in immunocompromised individuals at risk of developing active TB |
2. | Expenses associated with regimen and dosage should be reasonable for high burdened developing countries. |
3. | Immunization strategy must lower the risk of developing active pulmonary TB in adults previously vaccinated with BCG |
4. | Must protect against M.tb infections for more than 10 years subsequent to immunization |
5. | Minimum administrations requisite to elicit host protective responses |
6. | Evaluation of protective immune correlates by employing established assays |
7. | Must offer greater than 50% protective efficacy against established pulmonary TB |